Welcome to our dedicated page for Bicycle Therapeutics news (Ticker: BCYC), a resource for investors and traders seeking the latest updates and insights on Bicycle Therapeutics stock.
Bicycle Therapeutics plc (NASDAQ: BCYC) is a clinical-stage pharmaceutical company developing Bicycle molecules, Bicycle Drug Conjugates (BDC) and Bicycle Radioconjugates (BRC) for oncology indications. News about BCYC often centers on progress across its clinical pipeline, strategic collaborations, and financial updates that shape the company’s development plans.
Investors and observers following BCYC news can expect regular updates on clinical trials such as the Duravelo-1 Phase 1 study, the Duravelo-2 Phase 2/3 pivotal trial in metastatic urothelial cancer, and the Duravelo-3 and Duravelo-4 Phase 1/2 studies in Nectin-4–amplified breast cancer and non-small cell lung cancer. The company also reports on data presentations at major scientific meetings, including imaging and clinical data for BRC molecules targeting EphA2 and MT1-MMP.
Company news also covers strategic partnerships, including long-term arrangements with the UK Nuclear Decommissioning Authority, the United Kingdom National Nuclear Laboratory, and SpectronRx to support an end-to-end 212Pb radiopharmaceutical supply chain. Additional announcements highlight Board of Directors changes, formation and expansion of the Research and Innovation Advisory Board, and inducement grants to new employees under the 2024 Inducement Plan.
On this BCYC news page, readers can track press releases on quarterly financial results, regulatory interactions related to zelenectide pevedotin’s potential approval pathway, and anticipated milestones such as dose selection decisions and data disclosures. For those researching Bicycle Therapeutics stock, this news feed provides a centralized view of the company’s operational, clinical, and corporate developments over time.
Bicycle Therapeutics (NASDAQ: BCYC) has announced the approval of inducement awards for 18 new employees by its Board's Compensation Committee. The awards, granted on February 3, 2025, consist of non-qualified share options to purchase a total of 117,300 ordinary shares under the company's 2024 Inducement Plan.
The options have an exercise price of $13.39 per share, matching Bicycle's closing price on January 31, 2025. These options will vest over a four-year period, with 25% vesting after one year and the remaining shares vesting monthly over the subsequent 36 months, contingent on continued employment. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement material for employment.
Bicycle Therapeutics (NASDAQ: BCYC) announced updated Phase 1 data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer (mUC). The combination showed a 65% overall response rate among efficacy-evaluable patients, with 50% confirmed responses in 20 patients. The safety profile remained consistent with previous studies, with no patient withdrawals due to treatment-related adverse events.
The company outlined its 2025 strategic priorities, including expanding zelenectide pevedotin trials across multiple Nectin-4 associated cancers, with Phase 1/2 trials planned in breast cancer, lung cancer, and multiple tumors. Additional milestones include reporting Phase 2/3 Duravelo-2 dose selection data and advancing their radiopharmaceuticals pipeline.
As of September 2024, Bicycle reported $890.9 million in cash and cash equivalents, with an expected financial runway into second half of 2027.
Bicycle Therapeutics (NASDAQ: BCYC), a pharmaceutical company specializing in bicyclic peptide technology, has announced its upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management will deliver a podium presentation on Tuesday, Jan. 14, at 5:15 p.m. PT, which will be followed by a Q&A breakout session at 5:35 p.m. PT.
Investors and interested parties can access a live webcast of the presentation through the Investor section of Bicycle Therapeutics' website at www.bicycletherapeutics.com. The company will also make a replay of the webcast available on their website after the event.
Bicycle Therapeutics (NASDAQ: BCYC) has announced the granting of inducement awards to 12 new employees. The awards, approved by the Compensation Committee of the company's Board of Directors on January 2, 2025, consist of non-qualified share options to purchase a total of 67,300 ordinary shares.
The options were granted under Bicycle's 2024 Inducement Plan with an exercise price of $14.00 per share, matching the company's closing price on December 31, 2024. The options will vest over four years, with 25% vesting after one year and the remaining vesting monthly over 36 months, contingent on continued employment. These grants comply with Nasdaq Listing Rule 5635(c)(4) and are subject to the company's 2024 Inducement Plan terms and conditions.
Bicycle Therapeutics (NASDAQ: BCYC) announced significant data updates for its zelenectide pevedotin program. The drug showed a 60% overall response rate when combined with pembrolizumab in first-line metastatic urothelial cancer. In breast cancer patients with NECTIN4 gene amplification, the drug demonstrated a 62.5% response rate, while NSCLC patients with NECTIN4 gene amplification showed a 40% response rate.
The company plans to advance its development strategy focusing on NECTIN4 gene amplification, with Phase 1/2 trials in breast cancer, lung cancer, and multi-tumor planned for 2025. Dose selection and topline data from the Phase 2/3 Duravelo-2 trial are expected in 2H 2025.
Bicycle Therapeutics (NASDAQ: BCYC) has expanded its Clinical Advisory Board with three distinguished oncology experts to support its clinical oncology programs development. The new members include: Howard A. 'Skip' Burris III, president and chief medical officer of Sarah Cannon Research Institute; Markus Eckstein, senior consultant pathologist at University Hospital Erlangen; and Niklas Klümper, senior consultant for Urology & Genitourinary Oncology at University Hospital Bonn.
Each expert brings specialized experience: Burris in first-in-human therapies and FDA-approved treatments, Eckstein in genitourinary pathology and systems immunology, and Klümper in precision oncology and drug conjugate development.
Bicycle Therapeutics (NASDAQ: BCYC) announced that its Compensation Committee granted inducement awards to thirteen new employees on December 2, 2024. The awards consist of non-qualified share options to purchase 62,400 ordinary shares at an exercise price of $20.40 per share. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over 36 months. These grants were made under the company's 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Bicycle Therapeutics (NASDAQ: BCYC) announced upcoming presentations of data for zelenectide pevedotin at the 2024 San Antonio Breast Cancer Symposium. The company will present findings showing enhanced anti-tumor activity in triple-negative breast cancer patients with NECTIN4 gene amplification.
Additionally, Bicycle will announce topline data for zelenectide pevedotin plus pembrolizumab combination in first-line metastatic urothelial cancer patients, and monotherapy results in non-small cell lung cancer patients. The poster presentation, led by Dr. Niklas Klümper from University Hospital Bonn, is scheduled for December 12. A conference call to discuss these updates will be held on December 13.
Bicycle Therapeutics (NASDAQ: BCYC), a pharmaceutical company developing innovative therapeutics using its proprietary bicyclic peptide technology, has announced its participation in the upcoming Jefferies London Healthcare Conference. The company's management will engage in a fireside chat on November 19, 2024, at 10:30 a.m. GMT. Investors and interested parties can access a live webcast of the presentation through the company's website, with a replay available after the event.
Bicycle Therapeutics (NASDAQ: BCYC) announced that its Compensation Committee granted inducement awards to twelve new employees on November 1, 2024. The awards consist of non-qualified share options to purchase 56,700 ordinary shares under the company's 2024 Inducement Plan. The options have an exercise price of $23.44 per share, based on the closing price on October 31, 2024. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months, subject to continued employment.
FAQ
What is the current stock price of Bicycle Therapeutics (BCYC)?
What is the market cap of Bicycle Therapeutics (BCYC)?
